GlassScriptPhysician profile
Anthony W Buren
NPI 1467474460
$11,019.45
in general payments reported to CMS, 2019-2025
48 companies · $3,899 in 2025
The $3,899 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $883 · 2020: $614 · 2021: $941 · 2022: $919 · 2023: $681 · 2024: $3,082 · 2025: $3,899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,653 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,652.68 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,093.59 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $993.41 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $923.47 | 2021-2025 | Freestyle Libre 3, Eterna |
| Pfizer INC. | $806.85 | 2019-2025 | |
| Glaxosmithkline, LLC. | $749.78 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $568.51 | 2021-2025 | Zepbound, Mounjaro, Kisunla |
| Abbvie INC. | $529.57 | 2021-2025 | Ubrelvy |
| Amgen INC. | $461.30 | 2022-2025 | Repatha, Krystexxa, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $319.69 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Astellas Pharma US INC | $310.84 | 2019-2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $307.84 | 2020-2025 | Zoryve |
| Axsome Therapeutics, INC. | $256.23 | 2025 | Auvelity, Symbravo |
| Eisai INC. | $252.86 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $206.21 | 2024-2025 | Voquezna |
| Dexcom, INC. | $194.70 | 2024-2025 | Dexcom G6 Transmitter |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $169.82 | 2022 | |
| Nevro Corp. | $128.55 | 2024 | Senza |
| Daiichi Sankyo INC. | $121.19 | 2023-2025 | Injectafer |
| Xeris Pharmaceuticals, INC. | $114.91 | 2024-2025 | Keveyis |
| Wright Medical Technology, INC. | $114.26 | 2019 | |
| Medtronic, INC. | $108.44 | 2025 | Pulseselect |
| Otsuka America Pharmaceutical, INC. | $105.83 | 2024-2025 | Rexulti |
| Amarin Pharma, INC. | $95.58 | 2019 | |
| Novartis Pharmaceuticals Corporation | $94.12 | 2019 | |
| Sumitomo Pharma America, INC. | $87.77 | 2024-2025 | Gemtesa |
| Corium, LLC | $86.51 | 2024-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $85.19 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $80.38 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $75.49 | 2022-2024 | |
| Lundbeck LLC | $63.88 | 2024-2025 | Rexulti |
| Allergan, INC. | $57.65 | 2022 | |
| Antares Pharma, INC. | $52.71 | 2024-2025 | Xyosted |
| Janssen Pharmaceuticals, INC | $48.00 | 2022-2023 | Xarelto |
| Exact Sciences Corporation | $44.40 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Neurelis, INC. | $35.10 | 2021-2024 | Valtoco |
| Esperion Therapeutics, INC. | $34.22 | 2021-2025 | Nexletol |
| Boston Scientific Corporation | $32.74 | 2023-2025 | Watchman Flx, Watchman Access System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.45 | 2024 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $22.28 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $21.35 | 2023 | Epkinly, Imbruvica |
| Radius Health, INC. | $21.16 | 2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $19.11 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.20 | 2024 | Austedo Xr |
| Ultragenyx Pharmaceutical INC. | $17.17 | 2021 | |
| Electromed, INC. | $14.74 | 2024 | Smartvest |
| Alexion Pharmaceuticals, INC. | $14.51 | 2022 | |
| Phadia US INC. | $14.21 | 2025 | Immunocap |
| Alnylam Pharmaceuticals INC. | $13.68 | 2024 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Buren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.